Physicians' Academy for Cardiovascular Education

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

There is hope for treatment of HFpEF

Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Staggering results for weight reduction in T2DM

Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

New therapeutic options can make a difference for diabetic patients with high CV risk

Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Novel insights in the management and prognosis of pulmonary hypertension

Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Neurotoxin injection did not prevent the common complication of AF after cardiac surgery

Nov. 15, 2017 - AHA 2017 - Anaheim, CA, USA - Nathan Waldron, MD - Durham, NC, USA.

New ACC/AHA hypertension guidelines empasize risk assessment

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

A coordinated effort to organise STEMI care improved treatment time and patient outcomes

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - James Jollis, MD - Chapel Hill, NC, USA

Positive lesson from a negative trial comparing peri-operative continuation or interruption of DOAC therapy

Nov. 15, 2017 - AHA 2017 - Anaheim, CA - David H. Birnie, MD - Ottawa, ON, Canada

Machine learning program predicts that drinking more coffee lowers risk of CVD and stroke

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Laura M Stevens - Aurora, CO, USA

Highly adhering to a plant-based diet is associated with a lower risk of developing HF

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Sodium Bicarbonate and N-Acetylcysteine tested for the prevention of serious adverse outcomes

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Good BP measurement depends more on appropriate technique than on absence of staff

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA

Target for BP lowering differs between Europe and USA

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Restrictive transfusion is non-inferior to liberal approach during cardiac surgery

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - David Mazer - Toronto, Ont, Canada

Analogous to LDL-c, the lower the better also seems true for inflammation

Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Guideline differences regarding statin treatment affect ASCVD event prevention

Jan. 17, 2018 - Mortensen MB and Nordestgaard BG. - Ann Intern Med 2018
Statin eligibility differs substantially in the 5 major guidelines, and this impacts on the potential prevention of ASCVD events, which is a function of the number of eligible persons for statin therapy.

Statin eligibility differs substantially in the 5 major guidelines, and this impacts on the potential prevention of ASCVD events, which is a function of the number of eligible persons for statin therapy.

Women with AMI have higher CV death compared with men and may benefit from better adherence to guidelines

Jan. 16, 2018 - Alabas OA et al. - J Am Heart Assoc 2017
Women with AMI in Sweden had a higher excess mortality compared with men, which was reduced after adjustment for the use of guideline-indicated treatments.

Women with AMI in Sweden had a higher excess mortality compared with men, which was reduced after adjustment for the use of guideline-indicated treatments.

2017 ESC STEMI guidelines redefine important time points, with consequences for management choices

Jan. 16, 2018 - news

Two documents summarize the main messages of the ESC 2017 STEMI management guidelines, namely changes with respect to the 2012 version and ‘ten commandments’ to follow.

Impact traditional CVD risk factors reduces as patients get older

Jan. 15, 2018 - Lind L et al. - J Am Heart Assoc. 2018

In a longitudinal 40-years follow-up, the impact of 8 traditional CV risk factors on CVD declined with aging, with the exception of LDL-c for MI, and BMI and fasting glucose for HF.

Is the recommended therapy for heart failure with mid-range ejection fraction adequate?

Jan. 15, 2018 - Cleland JGF, et al. - Eur Heart J 2018
Beta-blockers improve left ventricular systolic function and reduce CV morbidity and mortality in heart failure patients with mid-range ejection fraction compared to placebo.

Beta-blockers improve left ventricular systolic function and reduce CV morbidity and mortality in heart failure patients with mid-range ejection fraction compared to placebo.

Online learning: LATEST FRONTIERS IN ANTICOAGULATION THERAPY

Featuring Dr. John Eikelboom: Key Questions for 2018 Clinical Practice Addressed

Jan. 12, 2018

View expert session focused on the latest developments in anticoagulation treatment.

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

BP before start therapy affects the relative benefit of BP-lowering therapy

Jan. 10, 2018 - Brunström M and Carlberg B. - JAMA Intern Med. 2018

A meta-analysis shows that the relative benefit of BP-lowering is evident when baseline SBP is ≥140mmHg, but not if it is <140 mmHg, particularly in primary prevention.

Differential associations seen between Lp(a) levels and stroke, depending on AF-status

Jan. 9, 2018 - Aronis KN et al., - J Am Heart Assoc. 2017

In a prospective community-based cohort, Lp(a) ≥50 mg/dL was associated with higher stroke risk in those without AF, but not in those with AF, nor with an elevated risk of AF.

Can LDL go too low? Lessons from 25 years of cholesterol lowering

Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA
Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.

Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.

Cardiovascular risk management: applying the latest insights to clinical care in Russia

PACE review based on the Cardiovascular Risk Master Class -Moscow, Russia (Oct 2016). Written by: Brouwer JR and Susekov A.

Download a free copy of this review on CV risk management in Russia.
Download a free copy of this review on CV risk management in Russia.

Download a free copy of this review on CV risk management in Russia. The documents discusses the current situation and considers how CVRM may be improved in Russia.

LDL-receptor expression correlates with the reduction in LDL-c in patients with homozygous FH on PCSK9 inhibitor treatment

Jan. 8, 2018 - Thedrez A, et al. - Arterioscler Thromb Vasc Biol. 2017

Ex vivo LDL-receptor expression is inversely associated with the plasma levels of LDL-c and apoB in HoFH patients before and after treatment with evolocumab.

Agenda